Sign in to fuzzto save your conversations, follow your research and come back anytime.
Cipla
SectorHealthcare
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
In the news
Cipla's Regulatory Crisis: License Cancellation and Compliance Challenges
Cipla disputes Pune warehouse closure as drug regulator reviews disposal
Cipla shares slip 1.2% despite Qilu biosimilar deal amid competition
Cipla's Pune Compliance Crisis: What Went Wrong
Cipla Pune Drug Licence Cancelled, FDA Withdraws Order After HC Raps
Regulatory Shifts and Strategic Bets: Corporate Performance Drivers Across Diversified Sectors
Cipla faces USFDA VAI classification at New York facility
Cipla posts record Q1 revenue vs Dr Reddy's semaglutide hit
Cipla shares rise 2.7% after USFDA approval for generic Advair Diskus
Cipla Makes Multiple Senior Leadership Changes Effective July 24, 2026
Cipla Q1 profit drops 39% YoY to ₹789 cr; shares gain 3.6%
Cipla shares surge 2.53% for fifth straight session
Experts Recommend Buy, Sell on Waaree Energies, Tata Motors PV
Nifty Pharma Extends Rally to 5-Session Winning Streak, Up 2%
SENSEX rises 0.38%, Cipla surges 5% on drug approvals
Sensex, Nifty rise 0.46% on US-Iran peace talks; Jio IPO boosts gains
Cipla names Shivam Puri CEO of One India Business
Cipla invests ₹4,000+ crore in respiratory, specialty manufacturing
Govt tightens cough syrup rules, pharma stocks fall up to 1.11%
Cipla Gets VAI Status for Goa Plant from USFDA
Company insights, generated from the most recent coverage.
FDA Commissioner Mundhe's zero-tolerance pledge on Schedule H advertising/storage/distribution signals broader statewide inspections of Cipla's warehouses and packaging compliance reviews across its prescription portfolio — not just Wadki.
Reactin Plus misbranding dents brand trust but not product credibility — no safety or efficacy issue, so physician prescribing dips ~10-15% in new scripts then recovers to baseline within 3-6 months; pain-management segment (GPs, ortho, rheum) most exposed.
With seized stock at just ~0.017% of quarterly revenue, litigation costs likely exceed the direct financial benefit — so Cipla's challenge is driven by precedent value and reputation rather than economics.